Nektar Therapeutics

Immunotherapy Advances Will Serve Aging Demand Yet Face Regulatory Hurdles

AnalystHighTarget

Not Invested

Community Contributor

Published

11 Aug 25

n/a

AnalystHighTarget's Fair Value

n/a

232.0%

-8.9%

232.0%

-8.9%

You can edit this narrative until Aug 11 9:19 PM. Then, changes will post as Updates.

Author's Valuation

US$12054.8% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$120

54.8% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

13.74%

Pharma revenue growth rate

0.66%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.96%

Calculation

US$12.84m

Earnings '28

261.71x

PE Ratio '28

US$3.36b

Market Cap '28

US$3.36b

Market Cap '28

23.30m

No. shares '28

US$144.21

Share Price '28

US$144.21 Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$118.46

Fair Value '25